Netherlands· NL-cd06aa7f5c65

Depakine i.v. 400, poeder voor injectievloeistof 400 mg

A valproic acid product containing natriumvalproaat, registered in Netherlands by Sanofi B.V.. The same ATC class is registered in 16 of our 19 countries.

ATC N03AG01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about natriumvalproaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Valproic acid is registered in 16 of 19 countries.

Countries holding a registration under ATC N03AG01 (valproic acid), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search valproic acid products by name

Valproic acid · ATC N03AG01

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of valproic acid costs, country by country.

Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Valproic acid · price per daily dose (1.5 g)

USD · FX 28 Sept 2026

CH Switzerland$1.61

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: NATRIUMVALPROAAT
Manufacturer: Sanofi B.V.
Country: Netherlands (NL)
ATC code: N03AG01
ATC class: Valproic acid
Defined daily dose: 1.5 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
14996

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

391 interactions on record for valproic acid.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check valproic acid against other medicines How interaction checks work

Valproic acid · interactions on record

391 records

9 severe
132 moderate
23 minor
189 info

Most severe, free to view

Glycerol phenylbutyrateA16AX09severe
BexaroteneL01XF03severe
VorinostatL01XH01severe
BexarotenL01XX25severe

38 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Valproic acid in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All valproic acid products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

Austria · Convulex
Bulgaria · Convulex, Конвулекс
Czechia · Convulex
Germany · Convulex
Estonia · Convulex
United Kingdom (Northern Ireland) · Convulex
Hungary · Convulex
Lithuania · Convulex
Latvia · Convulex
Poland · Convulex, Convulex 150
Portugal · Ácido Valpróico Generis
Romania · Convulex
Slovakia · Convulex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/66cbe6ec-d4e5-4fd7-a862-bafa5b6bb2ab
GET /v1/drugs/66cbe6ec-d4e5-4fd7-a862-bafa5b6bb2ab?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder en oplosmiddel voor oplossing voor injectie",
  "route": null,
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h14996_smpc.pdf",
  "strength": null,
  "atc_label": "Valproic Acid",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg14996",
  "excipients": [
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "NATRIUMVALPROAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h14996.pdf",
  "authorised_at": "1991/08/14",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "14996",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about valproic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console